World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
23074
World Ranking
17559
National Ranking
8784

Overview

Roberto Pili is affiliated with the University at Buffalo, State University of New York in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on several key subfields including Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Epidemiology.

Their work addresses a variety of main topics related to cancer biology and treatment, prominently featuring:

  • Renal cell carcinoma treatment
  • Prostate Cancer Treatment and Research
  • Head and Neck Cancer Studies
  • Epigenetics and DNA Methylation
  • Oral health in cancer treatment
  • Cancer Immunotherapy and Biomarkers
  • Histone Deacetylase Inhibitors Research

Roberto Pili has published extensively in several key venues, with frequent contributions in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Geriatrics
  • Cancers
  • Annals of Oncology

The following are some selected recent papers authored or co-authored by Roberto Pili, revealing the scope of research interests and collaborations:

  • CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors, 2020, JCO Precision Oncology
  • Ageing and COVID-19: What Is the Role for Elderly People?, 2020, Geriatrics
  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, 2023, Journal of Clinical Oncology
  • Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer, 2020, British Journal of Cancer
  • Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy, 2020, Nature Communications

Frequent co-authors of Roberto Pili include:

  • Poolakkad S. Satheeshkumar
  • Joel B. Epstein
  • Minu P. Mohan
  • Christopher Rupert
  • Донателла Рита Петретто

Best Publications

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.

    A. Passaniti;R. M. Taylor;R. Pili;Y. Guo

  • Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

    Huafeng Zhang;David Z. Qian;Yee Sun Tan;Kang Ae Lee

  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

    Naomi B. Haas;Judith Manola;Robert G. Uzzo;Keith T. Flaherty

  • NCCN clinical practice guidelines in oncology: kidney cancer.

    Robert J Motzer;Neeraj Agarwal;Clair Beard;Graeme B Bolger

  • Consensus guidelines for the use and interpretation of angiogenesis assays

    Patrycja Nowak-Sliwinska;Kari Alitalo;Elizabeth Allen;Andrey Anisimov

  • Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1α

    David Z. Qian;Sushant K. Kachhap;Spencer J. Collis;Henk M.W. Verheul

  • Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance

    Kristy J. Gotink;Henk J. Broxterman;Mariette Labots;Richard R. de Haas

  • Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma

    Ashley Orillion;Ashley Orillion;Ayumi Hashimoto;Nur P Damayanti;Li Shen

  • Targeting tumor angiogenesis with histone deacetylase inhibitors : the hydroxamic acid derivative LBH589

    David Z. Qian;Yukihiko Kato;Shabana Shabbeer;Yongfeng Wei

  • The histone deacetylase inhibitor NVP-LAQ824 Inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584

    David Z. Qian;Xiaofei Wang;Sushant K. Kachhap;Yukihiko Kato

  • Targeting tumor angiogenesis with histone deacetylase inhibitors.

    Leigh Ellis;Hans Hammers;Roberto Pili

  • Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

    Robert J. Motzer;Eric Jonasch;Neeraj Agarwal;Clair Beard

  • The α-Glucosidase I Inhibitor Castanospermine Alters Endothelial Cell Glycosylation, Prevents Angiogenesis, and Inhibits Tumor Growth

    Roberto Pili;Joan Chang;Richard A. Partis;Richard A. Mueller

  • Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1

    Olga V Volpert;Roberto Pili;Hashmat A Sikder;Thomas Nelius

  • VEGF165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo

    Judith Mühlhauser;Marsha J. Merrill;Roberto Pili;Hiroyuki Maeda

  • A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

    Elisabeth I. Heath;David W. Hillman;Ulka Vaishampayan;Shijie Sheng

  • Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-β-d-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab

    Judith E. Karp;Judith E. Karp;Ivana Gojo;Roberto Pili;Christopher D. Gocke

  • The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.

    Daniel Keizman;Maya Ish-Shalom;Peng Huang;Mario A. Eisenberger

  • Kidney cancer, version 1.2021: Featured updates to the nccn guidelines

    Robert J. Motzer;Eric Jonasch;Shawna Boyle;Maria I. Carlo

Frequent Co-Authors

Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Li Shen
Li Shen Icahn School of Medicine at Mount Sinai
Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Walter M. Stadler
Walter M. Stadler University of Chicago
Andrew J. Armstrong
Andrew J. Armstrong Duke University
Liang Cheng
Liang Cheng Brown University
Toni K. Choueiri
Toni K. Choueiri Harvard University
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, there are a variety of accessible and affordable online degree options in the United States. Online programs have become increasingly popular, offering flexibility for working professionals and non-traditional students.

Nursing is one of the fastest-growing fields in healthcare, and there are many educational pathways to consider. If you already hold an RN license, you can enhance your qualifications by completing an rn to bsn cheapest program online. These programs are often both cost-effective and convenient, allowing you to advance your career.

If you’re aiming for advanced practice or leadership, pursuing online nursing phd programs can open new opportunities in research and teaching. For those with non-nursing backgrounds, cheapest direct entry msn programs offer a fast track to becoming a registered nurse.

If you’re just starting out and are concerned about admission requirements, consider exploring easy nursing programs to get into. This can help you begin your healthcare career without unnecessary barriers.

Best Scientists Citing Roberto Pili

Trending Scientists